<DOC>
	<DOC>NCT01603615</DOC>
	<brief_summary>This study will evaluate the long-term safety of BOTOX® (botulinum toxin Type A) for the treatment of pediatric upper limb spasticity.</brief_summary>
	<brief_title>BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity</brief_title>
	<detailed_description />
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Minimum weight of 10 kg/22 lb Upper limb spasticity due to cerebral palsy or stroke Muscular dystrophy, myasthenia gravis, EatonLambert syndrome, amyotrophic lateral sclerosis, or mitochondrial disease Uncontrolled epilepsy Botulinum Toxin therapy of any serotype for any condition within the last 3 months History of surgical intervention of the upper limb within 1 year, or planned surgery of any limb during the study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>